

**FDA ADVISORY**  
No. **2023-1924**

08 SEP 2023

**TO: ALL PROFESSIONAL HEALTH SOCIETIES, CHIEFS OF HOSPITALS AND MEDICAL CENTERS, HEALTHCARE PROFESSIONALS AND ACADEMICIANS**

**SUBJECT: Call for Nomination as member of the Pharmacovigilance Advisory Committee (PVAdCom)**

Pursuant to Republic Act No. 9711, otherwise known as the “Food and Drug Administration (FDA) Act of 2009”, the FDA shall have the function to institute and strengthen the post marketing surveillance system in monitoring health products and incidents of adverse events involving such products. Also, the Republic Act No. 7394, otherwise known as the “Consumer Act of the Philippines,” declares that it is the policy of the State to promote the interest and general welfare of the consumer by implementing measures for: 1. protection against hazards to health and safety; 2. protection against deceptive, unfair and unconscionable sales acts and practices; 3. provision of information and education to facilitate decision making in choosing the products and exercise of rights of consumers.

To ensure the safety of drug products, the Pharmacovigilance Section was established under the Food and Drug Administration with responsibility for the effective implementation and coordination of the national pharmacovigilance system. It is also important that the Pharmacovigilance Section has access to an advisory committee that will provide technical advice/assistance to the FDA on matters and issues related to pharmacovigilance and safety of drug products.

In line with this, the FDA is starting the call for nomination to the following positions as member of the PVAdCom:

1. Pharmacovigilance Expert
2. Clinical Toxicologist
3. Clinical/Public Health Epidemiologist
4. Pharmacy/Pharmacology Expert
5. Clinical Medicine/Medical Specialist

The following are the required qualifications of the PVAdCom members:

- Recognized specialist in their respective field of expertise;
- With at least 5 years experience in their respective field;
- Willingness to disclose conflicts of interest



The nominees will be evaluated according to their educational attainment and field of expertise, relevance of work experience, relevance of training experiences within the last ten (10) years, publications and conflicts of interest.

We hope to receive the names and contact details of the nominees on or before 29 September 2023 and we shall reach out on the requirements and how to proceed with the application.

Kindly submit the list of the nominees at [clinicalresearch@fda.gov.ph](mailto:clinicalresearch@fda.gov.ph). If you have any questions or concerns, please do not hesitate to contact us through the same email address.

Thank you very much.



**DR. SAMUEL A. ZACATE**  
Director General